桃核承气汤辅助治疗脓毒症的系统评价与Meta分析
结果显示联合治疗可降低28天死亡率(RR=0.57,95%CI[0.38,0.86];低确定性)并改善炎症指标,但证据质量低,需谨慎解读。
要点
- 桃核承气汤辅助常规治疗或可降低脓毒症28天死亡率,但证据确定性低。
- 联合治疗可降低APACHE-Ⅱ、SOFA评分及WBC、PCT、CRP水平。
- 未观察到严重不良反应,但证据确定性极低。
核心结论
- 桃核承气汤作为脓毒症辅助治疗可能降低28天死亡率、改善炎症标志物并增强凝血功能,且未观察到严重不良反应。
- 鉴于纳入研究质量低,上述发现需谨慎解读,未来需大规模多中心RCT证实。
研究设计与样本
- 桃核承气汤作为常规治疗的辅助疗法,主要结局为28天死亡率,次要结局包括严重程度评分、炎症与凝血标志物及不良事件。
- 采用ROB 2.0和GRADE进行质量评价,多数研究被评为「some concerns」。
主要发现
- 与常规治疗相比,桃核承气汤联合常规治疗降低28天死亡率(RR=0.57,95%CI[0.38,0.86];低确定性)。
- 联合治疗降低APACHE-Ⅱ评分(MD=-2.37,95%CI[-3.12,-1.63];低确定性)和SOFA评分(MD=-1.41,95%CI[-2.12,-0.70];低确定性)。
- 联合治疗降低WBC(MD=-1.78 10^9/L,95%CI[-2.97,-0.59];低确定性)、PCT(MD=-1.20 ng/mL,95%CI[-1.71,-0.69];低确定性)和CRP(MD=-9.82 mg/L,95%CI[-13.98,-5.66];低确定性)。
- 未观察到严重不良事件(RR=0.67,95%CI[0.12,3.71];极低确定性)。
关键数值与推荐
- 28天死亡率:RR=0.57,95%CI[0.38,0.86],低确定性。
- APACHE-Ⅱ评分:MD=-2.37,95%CI[-3.12,-1.63],低确定性。
- SOFA评分:MD=-1.41,95%CI[-2.12,-0.70],低确定性。
- WBC:MD=-1.78 10^9/L,95%CI[-2.97,-0.59],低确定性。
- PCT:MD=-1.20 ng/mL,95%CI[-1.71,-0.69],低确定性;CRP:MD=-9.82 mg/L,95%CI[-13.98,-5.66],低确定性。
临床怎么用
- 在常规治疗基础上,可考虑联合桃核承气汤作为脓毒症辅助治疗,但需向患者说明证据确定性低。
- 联合治疗可能有助于改善炎症状态和器官功能评分,但应密切监测病情变化。
- 鉴于证据质量有限,不应替代常规治疗,临床决策需结合具体情况。
局限性
- 多数纳入研究存在「some concerns」的偏倚风险,证据确定性低至极低。
- 研究间异质性可能影响结果可靠性,需大规模多中心RCT进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This systematic review aimed to evaluate the clinical efficacy and safety of Taohe Chengqi (THCQ) decoction as an adjuvant therapy for sepsis, and to provide evidence for clinical practice. METHODS: Eight databases were systematically searched from inception until June 2024. The study included randomized controlled trials (RCTs) involving sepsis patients, where THCQ was used as an adjunctive therapy alongside conventional treatments. The primary outcome assessed was 28-day mortality rates, secondary outcomes included severity scores, inflammatory and coagulation markers, and adverse events. Two authors independently conducted the literature screening, data extraction, and evaluation of methodological quality. Meta-analysis was performed using RevMan 5.4.1 and Stata 17 software. The Risk of Bias (ROB) 2.0 and GRADE were employed for quality assessment. RESULTS: A total of sixteen RCTs involving 1,034 participants were included. Most of the studies were rated as having "some concerns" according to the ROB 2.0. Compared with conventional treatments, THCQ plus conventional treatments resulted in lower 28-day mortality rate (RR = 0.57, 95% CI [0.38, 0.86]; low-certainty), lower Acute Physiology and Chronic Health Evaluation II score (APACHE-Ⅱ) (MD = -2.37, 95% CI [-3.12, -1.63]; low-certainty), lower Sequential Organ Failure Assessment score (SOFA) (MD = -1.41, 95% CI [-2.12, -0.70]; low-certainty), lower white blood cell (WBC) (MD = -1.78 109/L, 95% CI [-2.97, -0.59]; low-certainty), lower procalcitonin (PCT) (MD = -1.20 ng/mL, 95% CI [-1.71, -0.69]; low-certainty), lower C-reactive protein (CRP) (MD = -9.82 mg/L, 95% CI [-13.98, -5.66]; low-certainty), and no serious adverse effects were observed (RR = 0.67, 95% CI [0.12, 3.71]; very low-certainty). CONCLUSION: Chinese medicine formula THCQ may offer potential benefits as an adjunctive treatment for sepsis patients, suggesting a reduction in the 28-day mortality rate, improvements in inflammatory markers, and enhancement of coagulation function, with no severe adverse reactions observed. Given the low quality of the included studies, the findings should be interpreted with caution. Future large-scale, multicenter RCTs are needed to confirm these findings and provide robust evidence. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024562595, identifier CRD42024562595.
引用
- Su Y, Su R, Shen C, et al. Classical formula Taohe Chengqi decoction as an adjuvant therapy for sepsis - a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2025. PMID: 40963685. doi:10.3389/fphar.2025.1499280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。